Last reviewed 2026-05-15 · How we verify

Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid

Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid is a Beta-lactam antibiotic Small molecule drug developed by Bayer. It is currently in Phase 3 development for Treatment of complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia, Treatment of skin and soft tissue infections.

Piperacillin/Tazobactam is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, while Amoxicillin/Clavulanic acid is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis and is protected from beta-lactamase degradation by Clavulanic acid.

Piperacillin/Tazobactam is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, while Amoxicillin/Clavulanic acid is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis and is protected from beta-lactamase degradation by Clavulanic acid. Used for Treatment of complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia, Treatment of skin and soft tissue infections.

At a glance

Mechanism of action

Piperacillin/Tazobactam and Amoxicillin/Clavulanic acid work by inhibiting the synthesis of the bacterial cell wall, ultimately leading to cell lysis and death. This mechanism is effective against a wide range of Gram-positive and Gram-negative bacteria. The addition of Tazobactam and Clavulanic acid provides protection against beta-lactamase degradation, allowing the antibiotics to remain effective against bacteria that produce these enzymes.

Approved indications

• Treatment of complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia
• Treatment of skin and soft tissue infections

Common side effects

• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Headache
• Rash

Key clinical trials

• Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO) (NA)
• Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
• Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) (PHASE3)
• Antibiotic Concentrations Among Critically Ill Patients
• Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
• Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand
• Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children (PHASE4)
• Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis. (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid CI brief — competitive landscape report
• Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid updates RSS · CI watch RSS
• Bayer portfolio CI

Frequently asked questions about Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid

Related

• Drug class: All Beta-lactam antibiotic drugs
• Manufacturer: Bayer — full pipeline
• Therapeutic area: All drugs in Infectious Diseases
• Indication: Drugs for Treatment of complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia
• Indication: Drugs for Treatment of skin and soft tissue infections
• Compare: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid vs similar drugs
• Pricing: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid cost, discount & access